Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers – GUTS

Pomerantz LLP filed a class action lawsuit against Fractyl Health, Inc. (NASDAQ: GUTS) for alleged securities fraud. The lawsuit claims defendants made materially false statements about the efficacy of Revita, their diabetes and obesity treatment device. On January 29, 2026, Fractyl disclosed disappointing six-month data from the REMAIN-1 Midpoint Cohort showing only 4.5% weight regain versus 7.5% in the sham arm, and revealed operational issues at one clinical site. The stock price fell 68.03% following the disclosure. The class period covers purchases between January 13, 2025 and January 29, 2026.